Stock Analiz

Oculis Holding AG OCS

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$7.64Market cap $426M
Open the interactive analysis →

Oculis Holding AG (OCS) is a healthcare company listed in the US with a market value of about $426M. In fiscal year 2025 it had revenue of $2M and net income of -$125M, a net margin of -8253.3%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 6% a year, a 5-year average ROIC of -70%.

About Oculis Holding

Oculis Holding is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $1M in 2020 to $2M in 2025, growth of about 6.0% a year. It was profitable in 0 of the last 6 years in our data.

Score: 1.2 / 5

Value0/5
Future growth4/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S380.9
P/B1.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-19.7%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)99.8%
Revenue growth (5 yrs, per year)6.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-7398.0%
ROIC (5-yr avg.)-69.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal year202520242023202220212020
Revenue$2M$757208$1M$987858$1M$1M
Net income-$125M-$95M-$106M-$42M-$20M-$17M
Free cash flow-$84M-$54M-$66M-$27M-$15M-$14M
EPS (diluted)$-2.24$-1.70$-1.90$-0.75$-0.36$-0.30
Net margin-8253.3%-12503.9%-10056.9%-4243.2%-1932.5%-1497.8%
ROIC-41.6%-99.6%-68.0%———

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Oculis Holding pay a dividend?

Not currently.

Is Oculis Holding a good stock to buy?

We do not give buy or sell advice. Oculis Holding scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.